Menelas Pangalos: About cirrhosis the liver, I think, also has a very high in medical need and the efficacy. The data around that, I think, is pretty interesting. And so I think we’ll get a readout there. And just to point out and I know you know this but the price points of diabetes versus heart failure, CKD and some of these different types of CKD because there are obviously various flavors of it. different price points relative to the diabetes price that has been based on.
Pascal Soriot: Michael Leuchten at UBS. Over to you, Michael.
Michael Leuchten: Two questions, please. One back to Susan. The Avanza trial is only asking an additional fixed question of that on top of carboplatin Postini, not a replacement question of chemotherapy which is a question that longer is asking. Given that the biomarkers being looked at here, just wondering why you wouldn’t also ask the replacement question in that Phase III? And then a question or for . Just wondering what the latest update would be for China given the NRDL process is now a yearly process. Are you happy with the pricing levels qualitatively that you’ve seen? Do you think it’s a stable system that allows you to operate more predictably going forward after what we saw last year?
Pascal Soriot: Thanks, Michael. So Susan, if you want to cover this one and we have Leon online. So the China question, Leon can take.
Susan Galbraith: So when adding carboplatin onto to DXD we don’t see a substantial increased problem with the tolerability of that. And again, you’re only giving the platinum for a set number of cycles. So this is a reasonably well-tolerated regimen. And as I said, the replacement question is being asked elsewhere across the program. So I think the question is really that we’re focusing on for Avanza is we’re going across histologies. We include squamous as well as non-squamous non-small cell lung cancer and across PD-L1 subgroups and then asking the question about the benefit in the biomarker patient population that are positive.
Pascal Soriot: Thank you, Susan. Leon, over to you.
Leon Wang: Yes. I think this year, we have several major drugs getting to NRDL renewal. And also, we are applying for our Cmax drug from Hamed — it’s a new entry. And also we have some application of new indication of ForSigand also for Lipaza. So right now, I don’t think we received the final result of price reduction level and also indication. But based on the latest information, I think the trend of NRDL is quite predictable and transparent, especially on the renewal — so based on the 2021 result, I think for Cigar, our anti-diabetes drug last year, I think, get quite a good result for revenue. And also, I think this year, we expect no big surprise on renewal and also quite many encouraging news on government encouragement on innovative drugs and also additional indecent and also our reimbursement renewal. So I think the trend on the China NRDL side is quite promising.
Pascal Soriot: Thank you, Leon. Michael, the other good thing about the system is that it’s becoming more formulaic, more driven by approaches or formulas that we can understand and therefore, Lensel, it’s a lot more predictable. Richard Parkes, Exane.
